Overview

CA-4948 in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2031-12-31

Target enrollment:

Participant gender:

Summary

Based on preclinical data from the Lim lab (WUSM), the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive tumor microenvironment (TME) to render chemo- and immunotherapies effective in GI malignancy. Therefore, this trial is designed to evaluate the combination of CA-4948 and standard chemoimmunotherapy in untreated advanced or metastatic biliary tract cancer.

Phase:

PHASE1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborators:

Curis, Inc.
Washington University Siteman Cancer Center

Treatments:

CA-4948
Cisplatin
durvalumab
Gemcitabine